In brief

Over 60 days, combined oral and vaginal treatment showed the greatest improvement. The findings concern the tested preparation and require confirmation in a more robust clinical design.

Three approaches compared

Oral hyaluronic acid is being investigated for vulvovaginal atrophy after menopause. Published on 3 October in Nutrition Journal, the trial followed 60 women for 60 days. It compared oral sodium hyaluronate ExceptionHYAL Blossom, a vaginal ovule and the two treatments together. Assessments covered vaginal health and symptoms reported by participants.

Findings from combined administration

The combined-treatment group showed the greatest improvement. For nutraceutical development, the study offers a starting point for investigating the contribution of oral administration alongside local treatment. The findings remain specific to an identified preparation: its composition and formulation characteristics are part of the conditions under which the results were obtained.

Early evidence requiring confirmation

The exploratory open-label design, absence of placebo and small sample leave questions about the magnitude and duration of benefit. The paper also discloses ROELMI HPC funding and the absence of public protocol registration. These features frame the need for further controlled comparisons, including before extending the conclusions to other formulations.

Why it matters

The study raises a question about the contribution of oral administration alongside an established local route, with implications for women’s-health formulation research.

Evidence limit

An exploratory open-label trial without placebo, funded by ROELMI HPC and without public protocol registration. Its duration does not establish long-term efficacy.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · Nutrition Journal · DOI 10.1186/s12937-026-01404-9